Cronic ocular surface diseases, including Dry Eye, Blepharitis, and MGD, affect approximately 10% of the global population, significantly impacting comfort and quality of life. These conditions are among the primary reasons for visits to eye care professionals, leading to symptoms such as blurred vision, redness, chronic pain, burning sensations, and irritation. Current treatments involve a combination of corticosteroids antibiotics (like Tobradex and Maxitrol), which are effective but limited by serious side effects, such as cataract formation and increased ocular pressure, necessitating their short-term use. Despite the chronic nature of Dry Eye, there is a lack of long-term effective treatments, highlighting the urgent need for new therapies that provide lasting relief without harmful side effects. The global market for Dry Disease is expected to reach $8.21 billion by 2030.